Table 3.

A: Surrounding Tumor Tissue Markers by Disease Type
		IBC Cases (N=45)	Treated IDC Cases (N=24)	Untreated IDC Cases (N=27)	P-Value
pS6	0	0	0	4 (14.8%)	<0.0001^
	1+	5 (11.6%)	2 (8.7%)	13 (48.2%)
	2+	37 (86.1%)	19 (82.6%)	10 (37%)
	3+	1 (2.3%)	2 (8.7%)	0
	No normal tissue
	Analysis N/A	2	1
pJAK2	0	2 (4.8%)	1 (4.2%)	20 (80%)	<0.0001^
	1+	21 (50.0%)	9 (37.5%)	5 (20%)
	2+	19 (45.2%)	13 (54.2%)	0
	3+	0	1 (4.2%)	0
	No normal tissue
	Analysis N/A	3		2
pSTAT3	0	18 (45.0%)	9 (37.5%)	24 (92.3%)	0.0001^
	1+	19 (47.5%)	13 (54.2%)	2 (7.7%)
	2+	3 (7.5%)	2 (8.3%)	0
	No normal tissue
	Analysis N/A	5		1
IL6	0	2 (4.8%)	3 (12.5%)	4 (15.4%)	0.0174^
	1+	30 (71.4%)	15 (62.5%)	22 (84.6%)
	2+	10 (23.8%)	6 (25%)	0
	No normal tissue
	Analysis N/A	3		1
CD68*	Median (range)	40 (4–100)	57.5 (10–100)	80 (30–105)	<.0001^^
	No Tumor Available	5
	No Tissue Available
CD163*	Median (range)	28 (3–80)	40 (18–75)	40 (6–90)	0.0013^^
	No Tumor Available	4
	No Tissue Available

B: Pairwise Comparisons of Expression Levels in Tumor Tissue – P-Values (Pairwise Comparisons of Table 3A)
	IBC vs Treated IDC	IBC vs Untreated IDC	Treated IDC vs Untreated IDC
pS6^	0.4889	<.0001	0.0002
pJAK2^	0.4945	<.0001	<.0001
pSTAT3^	0.8569	0.0002	<.0001
IL6^	0.4915	0.0065	0.0226
CD68^^	0.0051	<.0001	0.0005
CD163^^	0.0017	0.0034	0.7539

^{^}Fisher's Exact Test

^{^^}Kruskal-Wallis non parametric analysis of variance test

^*p<0.0167 is considered significant

^{^}Fisher’s Exact Test

^{^^}Wilcoxon Rank Sum Test